Skip to main content
Insights

CND Life Sciences Grows Its Syn-One Clinician Network™

By October 30, 2024No Comments

CND Life Sciences Grows Its Syn-One Clinician Network™

CND Life Sciences is continuing to add to its Syn-One Clinician Network, a directory of some of the hundreds of neurologists who are using the Syn-One Test® to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, and other neurological disorders.

It can be challenging for neurologists to diagnose certain neurological disorders, especially if you have symptoms that point to more than one condition. That’s where the Syn-One Test can help. It’s already been used by more than 2,000 neurologists and other clinicians in approximately 25,000 patient cases and has demonstrated greater than 95% accuracy.1*

If your doctor suspects you may have Parkinson’s disease, dementia with Lewy bodies, pure autonomic failure, multiple system atrophy, or REM sleep behavior disorder, the results of the Syn-One Test, along with your health history and symptoms, can help provide a more confident diagnosis. The test results may potentially help shorten the time to a correct diagnosis, which means you and your doctor can get started on making the most appropriate choices for your health.

You can use the directory to find a neurologist near you who offers the Syn-One Test to their patients. “We want the process of finding a neurologist to be as seamless as possible for our patients, and we hope this directory will be a new, accessible way for them to find the care and answers they need,” said Mackenzie Steinbach, Director of Clinical Services.

We’re always adding more doctors to the directory, so be sure to check back often if you don’t see someone in your area.

View the directory

*Prospective, blinded study (N=428) demonstrated 95.5% sensitivity and 96.3% specificity rates across synucleinopathies in patients with confirmed clinical diagnosis.
†REM sleep behavior disorder (RBD) is considered an early sign of a synucleinopathy. Ongoing research is being conducted in patients with RBD.

References:

  1. Gibbons CH, Levine T, Adler C, et al. Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. JAMA. 2024;331(15):1298–1306. doi:10.1001/jama.2024.0792